Luis Ortega-Paz, Fabiana Rollini, Francesco Franchi, Dirk Sibbing, Dominick J Angiolillo
{"title":"Switching Platelet P2Y<sub>12</sub> Receptor Inhibiting Therapies.","authors":"Luis Ortega-Paz, Fabiana Rollini, Francesco Franchi, Dirk Sibbing, Dominick J Angiolillo","doi":"10.1016/j.iccl.2024.11.001","DOIUrl":null,"url":null,"abstract":"<p><p>Antiplatelet therapy involving aspirin and a P2Y<sub>12</sub> receptor inhibitor is fundamental in managing patients with atherothrombotic disease. Switching between P2Y<sub>12</sub> inhibitors is frequently observed in clinical settings for various reasons, such as safety, efficacy, patient adherence, or cost concerns. Although it occurs often, the optimal method for switching remains a concern owing to potential drug interactions, which can result in either inadequate platelet inhibition and subsequent thrombotic events or low platelet reactivity and increased bleeding risks due to therapy overlap. This review offers practical guidance on switching P2Y<sub>12</sub> inhibitors, drawing from pharmacodynamic and clinical data.</p>","PeriodicalId":500993,"journal":{"name":"Interventional cardiology clinics","volume":"13 4S","pages":"e1-e30"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interventional cardiology clinics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.iccl.2024.11.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Antiplatelet therapy involving aspirin and a P2Y12 receptor inhibitor is fundamental in managing patients with atherothrombotic disease. Switching between P2Y12 inhibitors is frequently observed in clinical settings for various reasons, such as safety, efficacy, patient adherence, or cost concerns. Although it occurs often, the optimal method for switching remains a concern owing to potential drug interactions, which can result in either inadequate platelet inhibition and subsequent thrombotic events or low platelet reactivity and increased bleeding risks due to therapy overlap. This review offers practical guidance on switching P2Y12 inhibitors, drawing from pharmacodynamic and clinical data.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
